The University of Chicago Header Logo

Connection

Mark Kozloff to Organoplatinum Compounds

This is a "connection" page, showing publications Mark Kozloff has written about Organoplatinum Compounds.
Connection Strength

0.271
  1. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Dec; 12(4):248-54.
    View in: PubMed
    Score: 0.111
  2. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
    View in: PubMed
    Score: 0.037
  3. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist. 2017 03; 22(3):264-271.
    View in: PubMed
    Score: 0.035
  4. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Invest New Drugs. 2014 Aug; 32(4):700-9.
    View in: PubMed
    Score: 0.029
  5. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer. 2013 Dec 15; 119(24):4290-8.
    View in: PubMed
    Score: 0.028
  6. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012; 17(12):1486-95.
    View in: PubMed
    Score: 0.026
  7. Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study. Cancer Invest. 1990; 8(3-4):335-8.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.